Clinical trials: BRCA Mutation, open to volunteers
Breast Cancer Susceptibility Gene (BRCA1) Mutation, BRCA2 Mutation
Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene
The goal of this clinical trial is to determine whether an adapted version of a current cognitive-behavioural group therapy (CBT) protocol for cancer survivors to the specific needs of women who are carriers of the BRCA1/2…
- Conditions
- Breast Cancer Susceptibility Gene (BRCA1) Mutation, BRCA2 Mutation, Fear of Cancer Recurrence
- Trial name
- CBT-FCRBRCA1/2 (NCT06817694)
- Testing
- Cognitive-behavioral group therapy
- Where
- Canada
- Volunteers
- 250 people
- Sponsor
- CHU de Quebec-Universite Laval
Prostate Cancer, Castrate Resistant Prostate Cancer
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib…
- Conditions
- Prostate Cancer, Castrate Resistant Prostate Cancer, BRCA Mutation
- Trial name
- COROS (NCT06783127)
- Testing
- Olaparib
- Where
- 2 sites in Italy
- Volunteers
- 3,000 people
- Sponsor
- Santa Chiara Hospital
Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
This phase II trial studies how well olaparib with cediranib or AZD6738 works in treating patients with germline BRCA mutated breast cancer that has spread to other places in the body (advanced or metastatic).
- Conditions
- Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
- Trial name
- NCT04090567
- Testing
- Cediranib, Ceralasertib, Olaparib
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Surgery Date, Age
Quality of Life of Patients Who Have Undergone Bilateral Mastectomy
The investigators therefore aim to determine whether the type of mastectomy (preventive in a high-risk patient or therapeutic in a patient with a history of cancer), as well as the timing (immediate or delayed) and type of breast…
- Conditions
- Surgery Date, Age, BMI, Height
- Trial name
- RM BREAST Q (NCT07699913)
- Volunteers
- 115 people
- Sponsor
- University Hospital, Grenoble
Ovarian Cancer
Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Clinical Trial to evaluate the pharmacokinetic Characteristics, safety and Tolerability among CKD-215 and D215
- Trial name
- NCT07532148
- Testing
- CKD-215, D215
- Volunteers
- 24 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hot Flashes, Menopause Surgical
Acupuncture With/Without Self-acupressure for Post-oophorectomy Hot Flashes in BRCA Carriers
Risk-reducing surgery with salpingo-oophorectomy (RRSO) is the standard recommended treatment for all female carriers of BRCA genes 1 and 2.
- Trial name
- BRCA (NCT05331209)
- Testing
- Acupuncture, Acupuncture-Acupressure
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Shaare Zedek Medical Center
Advanced Solid Cancer, Metastatic Solid Tumor
Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN608 as monotherapy in adult patients with advanced solid tumors
- Conditions
- Advanced Solid Cancer, Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer
- Trial name
- NCT07088588
- Testing
- SYN608
- Where
- 2 sites in China
- Volunteers
- 105 people
- Sponsor
- Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
BRCA Mutation, Serous Tubal Intraepithelial Carcinoma
International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal Carcinomatosis
To prospectively assess the incidence of peritoneal carcinomatosis for women with isolated STIC (serous tubal intraepithelial carcinoma).
- Conditions
- BRCA Mutation, Serous Tubal Intraepithelial Carcinoma, Ovarian Carcinoma, Peritoneal Carcinoma
- Trial name
- STICRISC (NCT06393543)
- Testing
- No intervention, only registration
- Volunteers
- 600 people
- Sponsor
- Radboud University Medical Center
Ovarian Cancer
A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
This was a multicenter, open-label, randomized, crossover bioequivalence study to evaluate the pharmacokinetics and safety of BR2022 and BR2022-1 in Patients with deleterious or suspected deleterious germline BRCA-mutated…
- Trial name
- NCT07069335
- Testing
- Olaparib 150 MG
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Breast Cancer, BRCA 1 Gene Mutation
A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)
This study aims to learn whether a handheld robotic device, called the HandX, can help surgeons safely perform a minimally invasive nipple-sparing mastectomy.
- Conditions
- Breast Cancer, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Hereditary Breast Carcinoma
- Trial name
- ATHENA I (NCT07292246)
- Testing
- Endoscopic nipple sparing mastectomy, HandX endoscopic instrument
- Where
- Greece
- Volunteers
- 15 people
- Sponsor
- Vasileios Kalles
Breast Cancer
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
The purpose of this study is to learn more about the effects of your BRCA mutation on the ovaries. The BRCA gene can make it hard to conceive a child in the future. It may also bring on early menopause.
- Trial name
- NCT00823654
- Testing
- Blood draw and questionnaires
- Where
- 8 sites in United States
- Volunteers
- 609 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adjuvant Drug Therapy
Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations
The goal of this clinical trial is to evaluate the efficacy and safety of sacituzumab tirumotecan (sac-TMT) sequential capecitabine versus single-agent capecitabine as adjuvant intensified therapy in patients with high-risk…
- Trial name
- STARTER (NCT07628504)
- Testing
- Sacituzumab Tirumotecan (sac-TMT), Capecitabine
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Fudan University
Ovarian Cancer
Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy
This is an interventional (category 2), prospective, multicentric cohort study designed to demonstrate that the search, based on Circulating tumour DNA analysis, for a BRCA1/2 reversion mutation leading to restoration of its…
- Trial name
- ATROVA (NCT06588322)
- Testing
- Blood samples will be taken on several times (36 mL of blood taken at each time):
- Where
- 6 sites in France
- Volunteers
- 130 people
- Sponsor
- Institut Claudius Regaud
BRCA Mutation
MiniLap Vs Standard Laparoscopy in Prophylactic Bilateral Salpingo-oophorectomy in BRCA-Mutated Patients
The study hypothesis is that surgical treatment performed with MiniLap results in reduced postoperative pain in a population of patients undergoing prophylactic laparoscopic adnexal surgery.
- Trial name
- NCT06831747
- Testing
- Bilateral salpingo-oophorectomy - S-LPS, Bilateral salpingo-oophorectomy - PSS
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Azienda Sanitaria-Universitaria Integrata di Udine
Ovarian Cancer, BRCA Mutation
Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer
The overall goal of the Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer (PROMISE) study is to better understand how women may incorporate both polygenic risk score (PRS) and novel early detection…
- Trial name
- PROMISE (NCT06436248)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
BRCA-Mutated, Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer
Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer
The current standard of patients with de novo metastatic hormone sensitive prostate cancer (mHSPC) is to offer androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPI).
- Conditions
- BRCA-Mutated, Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer, Prostate Cancer
- Trial name
- CaBRA (NCT07591467)
- Testing
- Experimental
- Where
- 5 sites in France
- Volunteers
- 330 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
BRCA1 Mutation, BRCA2 Mutation
BRCA Mutation Carriers' Platform a Multicenter Study
Subjects who carry mutations in breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2 genes) are at higher risk of developing cancers.
- Trial name
- BRCA_ENDORSE (NCT07253051)
- Testing
- Registration of clinical datas in the platform
- Where
- 40 sites in Italy
- Volunteers
- 10,000 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Epigenomics, Transcriptomics
Epigenomic and Transcriptomic Analysis in BRCA Mutated Carriers With and Without Serous Tubal Intraepithelial Carcinoma
High-grade serous ovarian cancer (HGSOC) is the most lethal gynecologic malignancy and is typically diagnosed at an advanced stage, limiting opportunities for early detection and intervention.
- Conditions
- Epigenomics, Transcriptomics, BRCA Mutations
- Trial name
- PRE-PROBE (NCT07736300)
- Testing
- Peripheral blood sampling performed for germline DNA extraction and assessment of BRCA1/2 mutation status.
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Advanced or Metastatic Solid Tumors, Breast Cancer
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel…
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- ERADIC8 (NCT06395519)
- Testing
- ETX-19477
- Where
- 14 sites in United States
- Volunteers
- 120 people
- Sponsor
- 858 Therapeutics, Inc.
Breast Carcinoma, BRCA Mutation
Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation
Evaluation of the efficacy and safety of different adjuvant intensification regimens in early-stage BRCA1/2 mutant triple-negative breast cancer.
- Conditions
- Breast Carcinoma, BRCA Mutation, Adjuvant Drug Therapy
- Trial name
- NCT06405295
- Testing
- no intervention
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences